PMID- 36875311
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230307
IS  - 2732-7787 (Electronic)
IS  - 2732-7787 (Linking)
VI  - 3
IP  - 2
DP  - 2023 Mar-Apr
TI  - Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell 
      Carcinoma of the Head and Neck.
PG  - 264-271
LID - 10.21873/cdp.10211 [doi]
AB  - BACKGROUND/AIM: Prior immune-checkpoint inhibitors, weekly paclitaxel-cetuximab 
      was one of the few options for platinum-ineligible patients with recurrent/ 
      metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). This 
      real-world study analyzed the long-term outcomes of this regimen. PATIENTS AND 
      METHODS: A multicenter, retrospective, observational, cross-sectional, chart 
      review study was realized in nine hospitals of the Galician Group of Head and 
      Neck Cancer. Eligible population was adult platinum-ineligible patients with R/M 
      SCCHN (unfit to, or after progressing following EXTREME or other platinum-based 
      regimens) that received weekly paclitaxel plus cetuximab regimen as first- or 
      second-line (1L or 2L) between January 2009 and December 2014. The efficacy was 
      evaluated (1L-2L) in regards to overall survival (OS) and progression-free 
      survival (PFS), and safety was assessed as the incidence of adverse events (AEs). 
      RESULTS: Seventy-five R/M-SCCHN patients received the scheme (1L, n=50; 2L: 
      n=25). The mean age of the patients was 59 years (1L, 59.5 years; 2L, 59.2 
      years), 90% were male (1L, 96%; 2L, 79%), 55% were smokers (1L, 60.4%; 2L, 
      45.8%), and 61% presented ECOG performance status (PS) 1 (1L, 54%; 2L, 62.5%). 
      Median OS [interquartile range (IQR)] was 8.85 (4.22-40.96) months. Median PFS 
      (IQR) was 8.5 (3.93-12.55) (1L) and 8.8 (5.62-16.91) (2L) months. Disease control 
      rate was 60% (1L) and 85% (2L). Weekly paclitaxel-cetuximab was well tolerated in 
      1L/2L (cutaneous-toxicity, mucositis, neuropathy; mainly Grade 1-2). No grade 4 
      AEs were notified in 2L. CONCLUSION: Weekly paclitaxel-cetuximab is an active and 
      well tolerated therapeutical option in platinum-ineligible or after platinum 
      regimens in R/M-SCCHN patients.
CI  - Copyright 2023, International Institute of Anticancer Research.
FAU - Aguin, Santiago
AU  - Aguin S
AD  - Medical Oncology Department, Complejo Hospitalario Universitario de Santiago de 
      Compostela (CHUS), A Coruna, Spain.
FAU - Carral, Alberto
AU  - Carral A
AD  - Medical Oncology Department, Hospital Universitario Lucus Augusti (HULA), Lugo, 
      Spain.
FAU - Iglesias, Leticia
AU  - Iglesias L
AD  - Medical Oncology Department, Complejo Hospitalario Universitario de Ourense 
      (CHOU), Ourense, Spain.
FAU - Pena, Carolina
AU  - Pena C
AD  - Medical Oncology Department, Fundacion Centro Oncologico de Galicia (COG), A 
      Coruna, Spain.
FAU - Molina, Aurea
AU  - Molina A
AD  - Medical Oncology Department, Complejo Hospitalario Universitario de A Coruna 
      (CHUAC), A Coruna, Spain.
FAU - Costa, Marinha
AU  - Costa M
AD  - Medical Oncology Department, Hospital Ribera POVISA, Pontevedra, Spain.
FAU - Covela, Marta
AU  - Covela M
AD  - Medical Oncology Department, Hospital Universitario Lucus Augusti (HULA), Lugo, 
      Spain.
FAU - Gomez, Jesus Garcia
AU  - Gomez JG
AD  - Medical Oncology Department, Complejo Hospitalario Universitario de Ourense 
      (CHOU), Ourense, Spain.
FAU - Arroyo, Ramon Garcia
AU  - Arroyo RG
AD  - Medical Oncology Department, Complejo Hospitalario Universitario de Pontevedra 
      (CHOP), Pontevedra, Spain.
FAU - Huidobro, Gerardo
AU  - Huidobro G
AD  - Medical Oncology Department, Complejo Hospitalario de Vigo (CHUVI), Pontevedra, 
      Spain.
FAU - Simo, Rocio Vilches
AU  - Simo RV
AD  - Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, A 
      Coruna, Spain.
FAU - Medina, Ana
AU  - Medina A
AD  - Medical Oncology Department, Fundacion Centro Oncologico de Galicia (COG), A 
      Coruna, Spain.
LA  - eng
PT  - Journal Article
DEP - 20230303
PL  - Greece
TA  - Cancer Diagn Progn
JT  - Cancer diagnosis & prognosis
JID - 9918316186306676
PMC - PMC9949534
OTO - NOTNLM
OT  - Cetuximab-paclitaxel
OT  - first- and second-line of treatment
OT  - non-candidates to platinum
OT  - real world data
OT  - recurrent/metastatic squamous cell carcinoma of the head and neck
COIS- The Authors declare that there are no conflicts of interest regarding the 
      publication of this article.
EDAT- 2023/03/07 06:00
MHDA- 2023/03/07 06:01
PMCR- 2023/03/03
CRDT- 2023/03/06 04:08
PHST- 2022/11/04 00:00 [received]
PHST- 2022/11/15 00:00 [accepted]
PHST- 2023/03/06 04:08 [entrez]
PHST- 2023/03/07 06:00 [pubmed]
PHST- 2023/03/07 06:01 [medline]
PHST- 2023/03/03 00:00 [pmc-release]
AID - 10.21873/cdp.10211 [doi]
PST - epublish
SO  - Cancer Diagn Progn. 2023 Mar 3;3(2):264-271. doi: 10.21873/cdp.10211. eCollection 
      2023 Mar-Apr.